Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 13/20 | 0.69 |
| ▸ | NOS1 | P29475 | 11/20 | 0.69 |
| ▸ | NOS3 | P29474 | 8/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036602 | 0.88 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5036437 | 0.87 | NOS2 (0.58) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5034013 | 0.86 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL2835954 | 0.86 | NOS2 (0.54) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL4867989 | 0.83 | NOS2 (0.56) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL5038106 | 0.83 | NOS2 (0.51) | NOS2NOS1NOS3CYP2C9LMNA | |
| SCHEMBL4664600 | 0.83 | NOS2 (0.59) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5036501 | 0.83 | NOS2 (0.70) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5036979 | 0.82 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9FGFR3 | |
| SCHEMBL5033924 | 0.82 | NOS2 (0.52) | NOS2NOS1NOS3CYP2C9FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490366-B1 | ALKOXYPYRIDINE-DERIVATIVES | NYCOMED GMBH (DE) | 2008-01-23 | — | — | EP | claimed |
| US-7138399-B2 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2006-11-21 | — | — | US | claimed |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | US | claimed |
| EP-1490366-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA Pharma AG (DE) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080607-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2003-10-02 | — | — | WO | claimed |
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | UCL BUSINESS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | UCL BUSINESS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| EP-1490366-B1 | ALKOXYPYRIDINE-DERIVATIVES | NYCOMED GMBH (DE) | 2008-01-23 | — | — | EP | disclosed |
| US-7138399-B2 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2006-11-21 | — | — | US | disclosed |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1490366-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA Pharma AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080607-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885NOS3 3/4885 |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | NOS2, PNP, PTGIS | NOS2 1/4885NOS1 4/4885NOS3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.